NephroPlus, Asia’s biggest dialysis services provider and among the top five globally by treatment volume, will open its Initial Public Offering (IPO) on December 10, with bidding concluding on December 12. The company has announced a price band of ₹438–₹460 per share, along with a ₹41 employee discount.
The IPO includes a fresh equity issue of ₹353.4 crore and an offer for sale of 1,12,53,102 shares.
NephroPlus plans to utilise ₹129.1 crore from the fresh issue for new dialysis clinics across India and set aside ₹136 crore for repayment or pre-payment of existing borrowings.
Incorporated in 2009, the company operates India’s largest organised dialysis network across 288 cities in 21 states and 4 Union Territories. Internationally, NephroPlus runs 519 clinics, including 51 centres in the Philippines, Uzbekistan and Nepal. Its 165-bed Tashkent clinic is the largest dialysis centre globally.
Its services span haemodialysis, home-based dialysis, hemodiafiltration, holiday dialysis, and mobility-based dialysis solutions such as dialysis on call and dialysis on wheels.
The Indian dialysis market was valued at USD 818 million in FY24 and is expected to reach USD 1,979 million by 2029.
